OncoImmunology 1:6, 1-2; September, 2012; © 2012 Landes Bioscience

TAMable tumor-associated macrophages in response to innate RNA sensing

Tsukasa Seya,* Hiroaki Shime and Misako Matsumoto

Department of Microbiology and Immunology; Graduate School of Medicine; Hokkaido University; Sapporo, Japan

Key words: TLR3, TICAM-1, tumor-infiltrating macrophages, polyI:C, immunotherapy

Antitumor effect of PolyI:C (a viral dsRNA analog) has been attributed to dendritic cell (DC)-maturation activity, that drives antitumor NK cells, DC cross-presentation, cytotoxic T lymphocytes and many IFN-inducible genes. According to a recent paper, tumor-infiltrating M2 macrophages are found to become an additional antitumor effector through polyI:C response.

Interferon (IFN), now categorized as type I, was discovered by Isaacs and Lindeman in 1957. Soon after their discovery, it was expected to be a fascinating medicine opposing to virus infection and cancer development. Type I IFN inducing activity was assigned to the signature of double-stranded RNA generated from viruses, and its synthetic analog, polyI:C, was confirmed to serve as an effective inducer of type I IFN. Talmadge et al. showed that polyI:C mixed with polyL Lysine and methylcellulose (polyI:CLC) effected dramatic regression of syngenic implant tumors in mice. They suggested this reagent might be applied to antitumor therapy. In line with these reports, there have been many reports indicating that spontaneous tumor regression sometimes occurrs in cancer patients when they are exposed to viruses or viral vectors.

PolyI:C induces type I IFN and inflammatory cytokines. In addition, it may contribute to raising cellular immunity. According to recent progress in pattern recognition of innate immunity, polyI:C is a ligand for multiple receptors, including PKR, RIG-I, MDA5 and TLR3.[2] Virus replication usually amplifies dsRNA production inside the cytoplasm of affected cells and stimulates the cytoplasmic RNA sensors. In contrast, TLR3 is activated when dsRNA generated in infected cells is released and internalized into the endosome of bystander phagocytes,[2] such as dendritic cells (DC) and macrophages. dsRNA is delivered through a unique pathway involving Raftlin,[3] then the endosomal TLR3 passes the signal to the adaptor TICAM-1.[2] The multiple functionality of polyI:C may reflect its divergent receptor usage, and knockout mouse (KO) studies have therefore been indispensable for determination of the role of each receptor in antitumor immunity.

In mouse models, growth retardation of syngenic implanted tumor has been reportedly observed by administration of polyI:C, which is now attributable to liberated type I IFN and maturation of DC, that drives NK and killer T cells.[4,5] The mechanisms whereby these effector cells are introduced by dsRNA are being elucidated on a molecular level: the TLR3/TICAM-1 pathway for dsRNA recognition in DC is involved in effector driving. In a recent paper, Shime et al. additionally identified the third antitumor effector induced by ip polyI:C administration.[6] PolyI:C acted on tumor-infiltrating macrophages and induced tumor growth retardation in some tumor species. Administration of polyI:C rapidly (< 12 h) led to tumor hemorrhagic necrosis followed by tumor regression. The results appear to resemble an earlier report by Old's group on the TNFα-mediated fibrosarcoma regression.[7] In fact, TNFα participated in hemorrhagic necrosis in this case also. Shime et al. applied KO mice models for analyzing the signaling pathway by which the polyI:C-derived tumor regression occurs. Ultimately, their conclusion was that tumor-infiltrating macrophages (Mf) characterized by $CD11b^+$/$F4/80^+$/$Gr\text{-}1^{low}$ markers with sustaining tumor-supporting phenotype, M2, serves as a target for polyI:C and changes their properties to antitumor, M1-like, behaving like a tumoricidal effector. In these Mf, TLR3/TICAM-1 pathway, but not the IPS-1 pathway, is also mandatory for TNFα production and tumor regression. Indeed, the marker profile of the Mf was similar to those reported as M2 Mf or tumor-associated Mf (TAM). It is notable that they have high expression levels of TLR3. Hence, the polyI:C tumor growth retardation is mechanically multifarious and involves TNFα hemorrhagic necrosis.

TLR3 is highly expressed in $CD8^+$ splenic DC and $CD103^+$ non-lymphoid DC in mice,[8] and they are strong inducers for cross-priming of CD8 T cells,[5,8] namely cytotoxic T lymphocytes (CTL). TLR3-positive bone marrow-derived DC also reportedly induce type I IFN and potent antitumor NK cell activity.[4] Thus, polyI:C functions through $TLR3^+$ myeloid cells to facilitates antitumor cellular immunity encompassing at least three distinct routes, NK cell activation, CTL proliferation and conversion of TAM to an tumoricidal effector (**Fig. 1**). Hence,

*Correspondence to: Tsukasa Seya; Email: seya-tu@pop.med.hokudai.ac.jp
Submitted: 02/27/12; Revised: 03/02/12; Accepted: 03/02/12
http://dx.doi.org/



Figure 1. PolyI:C induces three antitumor effectors via different routes. Antitumor activity of polyI:C against tumor cells are assessed in mouse tumor-implant models. A unique point in this review is the third pathway where tumor-infiltrating myeloid cells are involved, effectively damages Lewis Lung carcinoma cells. This tumoricidal activity is mediated by the TICAM-1 pathway in the myeloid cells, and attributed to TNFα. Although polyI:C is i.p. administered, it acts on tumor-infiltrating Mf and converts them to antitumor effectors.

the Janeway/Medzhitov concept[9] may be adaptable to tumor immunology that pattern recognition receptor (PRR) stimulation by a specific ligand triggers innate immune response and facilitates establishment of the cellular immune system.

A tantalizing reagent for successful peptide vaccine therapy against cancer using tumor-associated antigens (TAA) with CD4/CD8 epitopes is adjuvant. Nevertheless, polyI:C therapeutic use has been very restricted in patients. This is because polyI:C has severe side effects, enterocolitis, arthralgia, fever, erythema and sometimes life-threatening hypotonic shock, which have prevented the clinical use of this dsRNA analog. However, a recent study reported that polyI:CLC is applicable to humans, although robust erythema and cytokine upregulation in serum are usually accompanied as side effects with expected therapeutic potential.[10] Dr. Steinman, having won the Nobel prize, proposed a polyI:C/TAA therapy for cancer patients if the TAA is identified in each case of the patients. Shime's data confirmed this issue and further clarified the importance of the TICAM-1 pathway in triggering induction of antitumor Mf in addtion to NK cells and CTL.[6] These sequential studies, together with the direct apoptotic effect of polyI:C on tumor cells, reinforce the need to establish a safer RNA derivative for human immunotherapy in the future.

References

1. Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, et al. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res 1985; 45:1058-65; PMID:3155990.
2. Matsumoto M, Oshiumi H, Seya T. Antiviral responses induced by the TLR3 pathway. Rev Med Virol 2011; 21:67-77; PMID:21312311; http://dx.doi.org/10.1002/rmv.680.
3. Watanabe A, Tatematsu M, Saeki K, Shibata S, Shime H, Yoshimura A, et al. Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation. J Biol Chem 2011; 286:10702-11; PMID:21266579; http://dx.doi.org/10.1074/jbc.M110.185793.
4. Ebihara T, Azuma M, Oshiumi H, Kasamatsu J, Iwabuchi K, Matsumoto K, et al. Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med 2010; 207:2675-87; PMID:21059856; http://dx.doi.org/10.1084/jem.20091573.
5. Azuma M, Ebihara T, Oshiumi H, Matsumoto M, Seya T. Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c+/CD8α+ dendritic cells. OncoImmunol 2012; In press.
6. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 2012; 109:2066-71; PMID:22308357; http://dx.doi.org/10.1073/pnas.1113099109.
7. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666-70; PMID:1103152; http://dx.doi.org/10.1073/pnas.72.9.3666.
8. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses and antiviral protection. J Immunol 2011; 186:2422-9; PMID:21242525; http://dx.doi.org/10.4049/jimmunol.1002845.
9. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7; PMID:9237759; http://dx.doi.org/10.1038/41131.
10. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 2011; 208:2357-66; PMID:22065672; http://dx.doi.org/10.1084/jem.20111171.

Microbiology and Immunology

Microbiol Immunol 2012; **56**: 1–9
doi:10.1111/j.1348-0421.2011.00403.x

REVIEW

In vitro models for analysis of the hepatitis C virus life cycle

Hussein H. Aly[1,2], Kunitada Shimotohno[3], Makoto Hijikata[4] and Tsukasa Seya[1]

[1]Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, [2]Laboratory of Viral Hepatitis and Host Defense, Hokkaido University Creative Research Institution, Kita-22, Nishi-7, Kita-ku, Sapporo 060-8638, [3]Research Institute, Chiba Institute of Technology, Narashino 275-0016, Chiba and [4]Department of Virology, Virus Research Institute, Kyoto University, Kyoto 606-8507, Japan

ABSTRACT

Chronic hepatitis C virus (HCV) infection affects approximately 170 million people worldwide. HCV infection is a major global health problem as it can be complicated with liver cirrhosis and hepatocellular carcinoma. So far, there is no vaccine available and the non-specific, interferon (IFN)-based treatments now in use have significant side-effects and are frequently ineffective, as only approximately 50% of treated patients with genotypes 1 and 4 demonstrate HCV clearance. The lack of suitable *in vitro* and *in vivo* models for the analysis of HCV infection has hampered elucidation of the HCV life cycle and the development of both protective and therapeutic strategies against HCV infection. The present review focuses on the progress made towards the establishment of such models.

Key words hepatitis C virus, HuH-7 cell, knockout mice, type I interferon.

Chronic HCV infection is a major cause of mortality and morbidity throughout the world, infecting approximately 3.1% of the world's population (1). Only a fraction of acutely infected individuals are able to clear the infection spontaneously, whereas approximately 80% of infected individuals develop a chronic infection (2, 3). Patients with chronic HCV are at increased risk for developing liver fibrosis, cirrhosis, and/or hepatocellular carcinoma. Currently, these long-term complications of chronic HCV infection are the leading indication for liver transplantation (4, 5). Because of the high incidence of new infections by blood transfusions in the 1980s before the discovery of the virus, and because morbidity associated with chronic HCV infection generally takes decades to develop, it is expected that the burden of disease in the near future will rise dramatically.

HCV is an enveloped flavivirus, with a positive-stranded RNA genome of approximately 9600 nucleotides. The coding region is flanked by 5′ and 3′ non-coding regions, which are important for the initiation of translation and regulation of genomic duplication, respectively. The coding region itself is composed of a single open reading frame, which encodes a polyprotein precursor of approximately 3000 amino acids. This polyprotein is cleaved by host and viral proteases into structural and NS proteins (Fig. 1). Replication of the HCV genome involves the synthesis of a full-length negative-stranded RNA intermediate, which in turn provides a template for the de novo production of positive-stranded RNA. Both these synthesis steps are mediated by the viral RNA-dependent RNA polymerase NS5B (6–8). NS5B lacks proofreading abilities, and this leads to a high mutation rate and the

Correspondence
Hussein H. Aly, Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan.
Tel: +81 11 706 5073; fax: +81 11 706 5056; email: ahussein@med.hokudai.ac.jp

Received 8 September 2011; revised 23 October 2011; accepted 3 November 2011.

List of Abbreviations: 3-D, three-dimensional; 3-D/HF, three-dimensional hollow fiber system; bbHCV, blood borne hepatitis C virus; HCV, hepatitis C virus; HPV/E6E7, human papilloma virus E6/E7 genes; IFN, interferon; IFNAR, interferon A receptor; IRES, internal ribosome entry site; ko, knockout; MDA-5, melanoma differentiation associated gene 5; MEF, mouse embryo fibroblasts; mir199, micro RNA 199; NS proteins, non-structural proteins; PPAR, peroxisome proliferator-activated receptor; RFB, radial flow bioreactor; RIG-I, retinoic acid-inducible gene I; TLR, Toll-like receptor; uPA, urokinase plasminogen activator.



Fig. 1. Genomic structure of HCV. Genomic organization of wild-type HCV. The HCV-RNA genome consists of a major open reading frame, encoding a single polyprotein, and an alternative reading frame encoding F-proteins with unknown functions. The cleavage of the polyprotein by viral and host cell proteases gives rise to the mature structural (core, envelope proteins E1 and E2, and p7) and NS viral proteins (NS2 through NS5B). The putative activities and functions of viral proteins are indicated. The IRES located in the 5′ non-coding region initiates ribosome binding and translation. Both the 5′ and 3′ non-coding regions are essential for viral RNA replication involving the RNA-dependent RNA polymerase NS5B. NTPase, nucleotide triphosphatase.

generation of numerous quasispecies. HCV isolates can be classified into seven major genotypes, which vary in sequence by more than 30%. In addition to the distinct prevalence and global spread of the virus, the genotype is an important factor determining disease progression and responses to antiviral therapy (9).

Currently, the only licensed treatment for HCV is the combination of (pegylated)-interferon-alpha (IFN-α) and ribavirin. Although the success rate of treatment has improved substantially, standard therapy is not effective in all patients. Moreover, severe adverse effects and high costs limit the compliance and global application of this treatment. The development of prophylaxis and novel therapeutics to treat HCV infection has been hampered by the lack of suitable *in vitro* and *in vivo* culture systems. In this review, we describe the development of *in vitro* culture systems for HCV.

Tissue culture-adapted HCV (sub-)genomic replicons

Dr Bartenschlager's group was the first to establish a convenient reproducible *in vitro* cell culture system for the study of HCV replication (10). They created antibiotic-resistant HCV genomes to select replication-competent viral clones by conveying antibiotic resistance to cells. This was achieved by replacing the structural protein-coding sequences, as well as p7 of the consensus genome Con1, by the neomycin resistance gene. In addition, a second IRES was introduced to promote translation of the non-structural protein-coding sequences important for viral replication (Fig. 2). Upon transfection of these so-called subgenomic replicons in specific cell lines, drug-resistant cell colonies were isolated in which high levels of viral replication occurred. Subsequent analysis confirmed that these HCV replicons indeed were capable of self-amplification through synthesis of a negative-strand replication intermediate, and could be stably propagated in cell culture for many years (10, 11).

HCV replication was supported by several cell types such as HuH6 (12), HepG2 (13), Li23 (14), and 293 cells (15), with the human hepatoma cell line HuH-7 being the most permissive (16). Interestingly, removal of replicon RNA from these cell clones by treatment with type 1 IFN rendered the cells more permissive to reintroduction of replicons, resulting in higher replication rates. Examples of these highly permissive cells are HuH-7.5 and HuH-7-Lunet cells (16, 17). The efficient replication in the replicon systems was found to depend on tissue-culture-adaptive mutations. Introduction of these specific mutations in the wild-type consensus sequence significantly enhanced viral replication *in vitro* (18–22). Mutational hot spots were found clustered primarily in the NS3, NS4B, and NS5A regions. The mechanisms behind the enhanced replication caused by these tissue-culture-adaptive mutations are still largely unknown, and the interesting fact that these mutations are not commonly found in patients suggests that these may have a toll on the viral fitness.

HCV replicons have proven to be extremely valuable for studies on the process of HCV replication, as well as for testing novel antiviral compounds that specifically target the protease activity of NS3 or the polymerase activity of NS5 (23).

Cell culture-derived infectious HCV

Studies using HCV replicons have provided detailed knowledge on the mechanisms of replication of HCV.



Fig. 2. HCV replicon system. The structural sequences (C, E1, E2, and p7) together with NS2 were replaced by a neomycin antibiotic-resistance gene, and an ECMV-IRES was introduced to drive translation of the remaining non-structural proteins. Neomycin selection of these double cistron (bicistronic) replicons in the hepatoma cell line Huh7 resulted in high-level HCV-RNA replication, depending on the gain of so-called 'tissue-culture' adaptive mutations mostly confined to the NS3, NS4B, and NS5A regions.

However, an apparent shortcoming of these models was that stable cell clones containing self-replicating replicons and expressing all viral proteins remained unable to release infectious HCV particles. The inability to secrete viral particles may be the consequence of adaptive mutations, which are needed to enhance viral replication rates, but at the same time may block viral assembly. Indeed, replicons without adaptive mutations show very low replication rates (16, 24). A different situation emerged when the first genotype 2a consensus genome was established (25, 26).

A subgenomic replicon constructed from a clone called JFH-1, isolated from a Japanese patient with fulminant hepatitis C, replicated up to 20-fold higher in HuH-7 cells as compared to Con1 replicons, and did not require adaptive mutations for efficient replication *in vitro* (26). Transfection of HuH-7 and HuH-7.5.1 cells with the *in vitro*-transcribed full-length JFH-1 genome or a recombinant chimeric genome with another genotype 2a isolate, J6, resulted in the secretion of viral particles that were infectious in cultured cells (Fig. 3), in chimeric mice, and in chimpanzees (27–29).

The infectivity of cells could be neutralized with antibodies against the HCV entry receptor CD81, antibodies against E2, or immunoglobulins from chronically infected patients. Importantly, the replication of cell-cultured HCV in this system was inhibited by IFN-α as well as by several HCV-specific antiviral compounds (29). Since 2005, chimeric JFH-1-based genomes have been constructed of all seven known HCV genotypes. Similar to the J6-JFH-1 chimera, in these so-called intergenotypic recombinants, the structural genes (core, E1, and E2), p7, and NS2 of JFH-1 were replaced by genotype-specific sequences which often resulted in lower infectious virion production than



Fig. 3. JFH1 infectious system. Full-length JFH1-RNA is transcribed *in vitro*, and transfected to HuH-7-derived cell lines. JFH1 replicates in these cells, and produce infectious virions in the medium. The medium is collected, concentrated, and used to infect naive cells. Hence, the entire HCV life cycle was reproduced for the first time *in vitro*.

wild-type JFH-1 (30–32). Most NS proteins of intergenotypic chimeras originate from JFH-1, and therefore these genomes are unlikely to reflect genotype-specific characteristics of replication. However, these intergenotypic chimeras may become critically important in the study of differences in HCV entry or to assess the efficacy of HCV entry inhibitors. Interestingly, production of infectious genotype 1a HCV in cells transfected with synthetic RNA (H77-S) derived from a prototype virus (H77-C) was also reported (33). H77-S carries adaptive mutations that promote efficient viral RNA replication in HuH-7.5 cells. These mutations are located within the NS3/4A protease complex, and the NS5A protein (34) H77-S showed similar replication efficiency to JFH-1 isolate; however, it showed lower expression of HCV core protein, and lower production of infectious HCV particles (33).

Serum-derived HCV infection

The previously mentioned models used to study HCV infection are based on subclones of HuH-7 cells infected with JFH1 recombinant virus or its derivatives (27). HuH-7 cells and its subclones, however, do not support the entire life cycle of the bbHCV present in the blood of patients (35). Moreover, HCV has considerable diversity and variability. It is generally classified into six major genotypes and more than 100 subtypes (36). JFH1, however, is a single isolate of HCV genotype 2a that was originally derived from a patient with rare fulminant hepatitis (27). Thus, usage of HCV particles isolated from patient serum could be more useful to study authentic HCV infection.

Many researchers have attempted to develop an *in vitro* system for bbHCV (37–39). These current systems, however, are still insufficient due to their low efficiency for infectivity and replication of bbHCV. Normal human hepatocytes are the ideal system in which to study HCV infectivity. When cultured *in vitro*, however, they proliferate poorly and divide only a few times (40). Continuous proliferation could be achieved by introducing oncogenes, the HPV/E6E7 immortalized multiple cell types that were phenotypically and functionally similar to the parental cells (41–45). We established a human primary non-neoplastic hepatocyte cell line transduced with the HPV18/E6E7 that retained primary hepatocyte characteristics even after prolonged culture (35). We further improved the susceptibility of HPV18/E6E7-immortalized hepatocytes (HuS-E/2 cells) to bbHCV infectivity by impairing the innate immune response of these cells through suppression of interferon regulatory factor-7 (IRF-7) expression. These cells were useful to assay infectivity of HCV strains other than JFH-1, HCV replication, innate immune system engagement of HCV, and screening of anti-HCV agents. This infection system using non-neoplastic cells also suggested that IRF-7 plays an important role in eliminating HCV infection. Using this system, the suppressive effect of tamoxifen and mir199 on HCV replication was reported (46, 47).

Three-dimensional culture

A major limitation of the immortalized hepatocytes infection system was the failure to produce infectious HCV particles. Because the 3-D cell culture condition more closely reproduces the *in vivo* environment of hepatocytes (48), culturing these cells in this manner may support the entire HCV life cycle. Similarly, a previous report showed the production of HCV particles from the FLC4 hepatocyte line transfected with HCV-RNA and cultured in a 3-D radial-flow bioreactor (RFB). The RFB system is composed of a dedicated device containing 1×10^9 FLC4 cells with a culture area of 2.7 m^2. A more convenient, smaller and easy to use 3-D culture system is required for the study of the several aspects of bbHCV infection. (49). A hybrid artificial liver support system was developed using animal hepatocytes cultured in a 3-D/HF. This bioartificial liver showed several characteristic features of liver tissue for more than 4 months (50–52).

By growing our HuSE/2 cells in a similar 3-D culture (53) the gene expression profile was improved to more closely match that of human primary hepatocytes. We used this small 3-D culture system and showed it to be ideal for culturing HuS-E/2 cells for the study of bbHCV infection (Fig. 4) (54). Using this system we observed not only the enhancement of HCV replication, but also the production of infectious HCV particles in the medium using the 3-D/HF system. The cell mass formed by the 3-D culture system, most likely the polar character, was essential for the life cycle of bbHCV. Using microarray comparison of gene expression between 2-D and 3-D cultured cells, we found a higher activation of the PPAR-α signaling pathway which was shown to be important for the improvement of HCV replication in 3-D culture. Suppression of the PPAR-α signaling pathway using its antagonist MK886 markedly suppressed HCV replication in two different cell lines (53). A recent study showed that the induction of PPAR-α or PPAR-γ led to the suppression or enhancement of HCV replication, respectively, in HuH-7 cells (55). Using HuH-7-derived clones, three different independent studies confirmed our data, showing the suppression of HCV replication by PPAR-α blockers such as (MK886) (56, 57) or 2-chloro-5-nitro-*N*-(pyridyl) benzamide (BA) (58). Furthermore, no effect of PPAR-γ was observed on HCV replication (58).

Delayed production of infectious particles was also observed in cells infected with some HCV strains after prolonged culture (54). It is likely that mutation of the HCV



Fig. 4. 3-D hollow fiber culture. HuS-E/2 suspension was injected into the lumen of the hollow fiber system (HF; Toyobo Co., Osaka, Japan). The bundles were centrifuged to induce organoid formation. The lower 1.5 cm containing the organoid formation was then cut and cultured in 12-well plates (two capillary bundles per well) with gentle rotation using serum-free medium (Toyobo Co.) in a CO_2 incubator at 37°C. The number of cells was adjusted to 3×10^5 cells per two-capillary bundle at the start of each experiment.

genome and/or selection of clones during prolonged culture improved the productivity of infectious particles. This lack of production of infectious particles soon after infection may serve to avoid an early strong response from the host immune system, and demonstrates a novel mechanism of latent infection by HCV. Similarly, fluctuation in HCV proliferation was observed during the prolonged culture of 3-D-HuS-E/2 cells infected with bbHCV (54); this fluctuation was associated with a change in viral quasispecies, suggesting that an HCV strain having a growth advantage proliferates selectively and dominantly in these culture conditions. Because the progressive emergence of each dominant strain was only temporary, it is highly likely that the infection and proliferation of such an HCV strain is suppressed by cellular mechanism(s). Our results showed two cellular mechanisms functioning to do this. The first is the involvement of the innate immune system, as evidenced by the secretion of IFN-α during the first week of infection. The second mechanism is HCV-induced apoptosis. Although HCV-induced apoptosis was not found when HCV-1b was used for infection, it was found in all cases where HCV-2a was used, suggesting a higher cytopathic tendency of the HCV-2a genotype.

Mouse cells permissible to HCV infection

The development of prophylaxis and novel therapeutics to treat HCV infection has been hampered by the lack of suitable animal models, a deficit resulting from the limited species tropism of HCV. Chimpanzees are the only available immunocompetent *in vivo* experimental system, but their use is limited by ethical concerns, restricted availability and prohibitively high costs (59).

A convenient small-animal model supporting the HCV life cycle could significantly accelerate the preclinical testing of vaccine and drug candidates, as well as facilitate *in vivo* studies of HCV pathogenesis. A murine model was described in which overexpression of a uPA transgene resulted not only in neonatal bleeding disorders, but also in severe liver toxicity (60). Importantly, the diseased liver could be replaced by donor hepatocytes of murine origin, as well as by hepatocytes from rats, woodchucks, and humans once the uPA transgenic mice were backcrossed on an immunodeficient background. Mice with chimeric human livers that were inoculated with serum from HCV-positive donors developed prolonged HCV infections with high viral titers and evidence for active replication of the virus in chimeric human livers (61). At present, the chimeric human liver uPA/SCID mouse model is physiologically closest to a natural human infection and therefore represents the most successful small-animal model for HCV infection. Several shortcomings, however, limit its widespread use and application. Most importantly, the immunodeficiency required to allow successful xenotransplantation precludes studies on the adaptive immune response, immunopathology, and active immunization strategies (vaccine development). Second, only a few laboratories have reported successful generation of these chimeras, because this model requires high-quality human donor hepatocytes and the actual transplantation is difficult to carry out in small animals with a tendency to bleed. Finally, the efficacy of human hepatocyte engraftment is highly variable



Fig. 5. Induction of interferon response by viral RNA. The cell detects viral RNA through the endosomal RNA sensor TLR3, and the cytoplasmic RNA sensors RIG-I and MDA5. Both pathways will lead to the activation of TBK-1 and IKK-I kinases, through the TICAM-1 adaptor molecule in the case of TLR3, or IPS-1 in the case of RIG-I and MDA5. These kinases will induce phosphorilization of interferon regulatory factor (IRF)-3, which will then dimerize and translocate to the nucleus. IRF-3 will then bind to the IRF response elements (IRF-RE) of IFN-β and lead to the induction of IFN-β expression. The IFN-β that is produced and secreted binds to the IFN receptor in an autocrine or paracrine manner to direct Janus Kinase Signal Transducer and Activator of Transcription (JAK-STAT) signaling and the interferon-stimulated gene factor 3 (ISGF3)-dependent expression of IRF-7 and other interferon-stimulated genes (ISG). IRF-7 will be phosphorylated by the activated TBK-1 and IKKε kinases, and form homo, or hetero-dimers with IRF-3, leading to further induction of IFN-β and -α genes. This signaling serves to amplify the IFN response by increasing the expression of IFN-β, IFN-α subtypes and ISG in a positive feedback loop.

in these animals, ranging from approximately 2% to 92% after additional treatment with an antibody to asialo- GM-1 (62).

The successful establishment of the HCV life cycle in mouse hepatocytes is another tempting alternative to overcome these problems. In addition to missing or incompatible positive regulators of HCV replication, dominant-negative restriction factors might be present in mouse hepatocytes. Altered or exacerbated innate antiviral responses, the inability of HCV proteins to overcome murine defenses, or mouse-specific restriction factors similar to those that control retroviral infection, such as Fv1, TRIM5α or APOBEC3 cytidine deaminases, could impair HCV replication in mouse cells.

In mammalian cells, the host detects and responds to infection by RNA-viruses, including HCV, by primarily recognizing viral RNA through several distinct pathogen recognition receptors (PRR), including the cell surface and endosomal RNA sensors TLR3 and TLR7, and the cytoplasmic RNA sensors RIG-I and MDA5 (Fig. 5) (63). The detection of virus infection by these receptors leads to the induction of IFN and their downstream IFN-inducible anti-viral genes through distinct signaling pathways (64). Type I IFN is an important regulator of viral infections in the innate immune system (65). Another type of IFN, IFN-lambda, affects the prognosis of HCV infection, and its response to antiviral therapy (66,67). Variations in the type or intensity of the antiviral response between hosts are known to restrict the tropism of certain viruses, such as myxoma virus, which is only permissive in mouse cells that have impaired IFN responses. Similarly, we previously reported that the impairment of IRF-7, and suppression of the interferon response improved HCV replication in immortalized primary human hepatocytes. (35)

Mutations impairing the function of the RIG-I gene and the induction of IFN were essential in establishing HCV infectivity in human HuH-7.5 cells (68). Similarly, the HCV-NS3/4a protease is known to cleave the IPS-1 adaptor molecule, inducing further downstream blocking of the IFN-inducing signaling pathway (69). These data clearly demonstrate that the host RIG-I pathway is crucial for suppressing HCV proliferation in human hepatocytes. Using a similar strategy, we investigated whether suppressing the antiviral host innate immune system conferred any advantage on HCV proliferation in mouse hepatocytes (70). We examined the possibility of HCV replication



Fig. 6. Establishment of mouse hepatocyte lines permissive to J6/JFH1.
Immunofluorescence detection of J6JFH1 proteins' expression 5 days after transfection of J6JFH1-RNA through electroporation into wild-type, IRF-3-ko, IRF-7-ko, TICAM1-ko, IPS-1-ko, and IFNAR-ko, freshly isolated primary hepatocytes. A highly sensitive polyclonal antibody extracted from HCV-patient serum (AbS3) was used for the detection.

in mice lacking the expression of key factors that modulate the type I IFN-inducing pathways (Fig. 6). Only gene silencing of IFNAR or IPS-1 was sufficient to establish spontaneous HCV replication in mouse hepatocytes.

To establish a cell line permissive for HCV replication, which is required for further *in vitro* studies of the HCV life cycle in mouse hepatocytes, we immortalized IFNAR- and IPS-1-ko mice hepatocytes with SV40 T antigen. Upon expression of the human (h)CD81 gene, these newly established cell lines were able to support HCV infection and replication for the first time in mouse hepatocytes. Using these cell lines, we demonstrated that the suppression of IPS-1 enhances HCV infection and replication in mouse hepatocytes through the suppression of both IFN induction and an IFN-independent J6JFH1-induced cytopathic effect. We also showed for the first time the importance of the HCV structural region for viral replication, as JFH1 chimera containing the J6 structure region showed a privilege for spontaneous replication over full-length JFH1 or the subgenomic JFH1 replicon. IRF-3-ko MEF were previously shown to support HCV replication more efficiently than wild MEF (71). As the knockout of IPS-1 mainly suppresses signaling in response to virus RNA detection, and maintains an intact IFN response and induction to other stimulants, it may result in minimum interference to adaptive immune responses as compared to IRF-3 or IFNAR-ko.

Conclusion

We have established an *in vitro* culture system that can support the entire life cycle of a variety of HCV isolates and genotypes. Although this *in vitro* model system may not completely reproduce the *in vivo* situation, we believe it is the first *in vitro* system showing HCV strain-dependent virus/cell interaction including induction of cellular apoptosis and/or evasion from the cellular innate immune response, which may make it a good tool for the analysis of virus/host interaction, together with the development of new anti-HCV strategies for the different bbHCV strains. We have also established hepatocyte lines from IPS-1-ko mice that support HCV replication and infection. These cell lines will be very useful in identifying other species' restriction factors and viral determinants required for the further establishment of a robust and efficient HCV life cycle in mouse hepatocytes. Further development of hCD81-transgenic IPS-1-ko mice may serve as a good model for the study of immunological responses against HCV infection. This mouse model can be used as a backbone for any further future models supporting robust HCV infectivity for the study of HCV pathogenesis, propagation and vaccine development.

ACKNOWLEDGMENT

The author wish to thank Dr. Jin Takahashi from the Japanese NIH, NIID for his help designing figure 5 in this paper.

DISCLOSURE

The authors declare no financial or commercial conflict of interest.

REFERENCES

1. Seto W.K., Lai C.L., Fung J., Hung I., Yuen J., Young J., Wong D.K., Yuen M.F. (2010) Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. *J Hepatol.*
2. Conry-Cantilena C., Vanraden M., Gibble J., Melpolder J., Shakil A.O., Viladomiu L., Cheung L., Dibisceglie A., Hoofnagle J., Shih J.W., Kaslow R., Ness P., Alter H.J. (1996) Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. *N Engl J Med* **334**: 1691–6.
3. Alter M.J., Kruszon-Moran D., Nainan O.V., Mcquillan G.M., Gao F., Moyer L.A., Kaslow R.A., Margolis H.S. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* **341**: 556–62.
4. Brown R.S. (2005) Hepatitis C and liver transplantation. *Nature* **436**: 973–8.

5. Shepard C.W., Finelli L., Alter M.J. (2005) Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* **5**: 558–67.
6. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. (2004) Structural biology of hepatitis C virus. *Hepatology* **39**: 5–19.
7. Moradpour D., Penin F., Rice C.M. (2007) Replication of hepatitis C virus. *Nat Rev Microbiol* **5**: 453–63.
8. Bartenschlager R., Lohmann V. (2000) Replication of hepatitis C virus. *J Gen Virol* **81**: 1631–48.
9. El-Farrash M.A., Aly H.H., Watashi K., Hijikata M., Egawa H., Shimotohno K. (2007) In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin. *Microbiol Immunol* **51**: 127–33.
10. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* **285**: 110–3.
11. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. (2001) Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. *J Virol* **75**: 1252–64.
12. Windisch M.P., Frese M., Kaul A., Trippler M., Lohmann V., Bartenschlager R. (2005) Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. *J Virol* **79**: 13778–93.
13. Date T., Kato T., Miyamoto M., Zhao Z., Yasui K., Mizokami M., Wakita T. (2004) Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. *J Biol Chem* **279**: 22371–6.
14. Kato N., Mori K., Abe K., Dansako H., Kuroki M., Ariumi Y., Wakita T., Ikeda M. (2009) Efficient replication systems for hepatitis C virus using a new human hepatoma cell line. *Virus Res* **146**: 41–50.
15. Ali S., Pellerin C., Lamarre D., Kukolj G. (2004) Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. *J Virol* **78**: 491–501.
16. Blight K.J., Mckeating J.A., Rice C.M. (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *J Virol* **76**: 13001–14.
17. Friebe P., Boudet J., Simorre J.P., Bartenschlager R. (2005) Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. *J Virol* **79**: 380–92.
18. Lohmann V., Korner F., Dobierzewska A., Bartenschlager R. (2001) Mutations in hepatitis C virus RNAs conferring cell culture adaptation. *J Virol* **75**: 1437–49.
19. Lohmann V., Hoffmann S., Herian U., Penin F., Bartenschlager R. (2003) Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. *J Virol* **77**: 3007–19.
20. Krieger N., Lohmann V., Bartenschlager R. (2001) Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. *J Virol* **75**: 4614–24.
21. Blight K.J., Mckeating J.A., Marcotrigiano J., Rice C.M. (2003) Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. *J Virol* **77**: 3181–90.
22. Blight K.J., Kolykhalov A.A., Rice C.M. (2000) Efficient initiation of HCV RNA replication in cell culture. *Science* **290**: 1972–4.
23. Bartenschlager R. (2005) The hepatitis C virus replicon system: from basic research to clinical application. *J Hepatol* **43**: 210–6.
24. Pietschmann T., Lohmann V., Kaul A., Krieger N., Rinck G., Rutter G., Strand D., Bartenschlager R. (2002) Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. *J Virol* **76**: 4008–21.
25. Kato T., Furusaka A., Miyamoto M., Date T., Yasui K., Hiramoto J., Nagayama K., Tanaka T., Wakita T. (2001) Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. *J Med Virol* **64**: 334–9.
26. Kato T., Date T., Miyamoto M., Furusaka A., Tokushige K., Mizokami M., Wakita T. (2003) Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. *Gastroenterology* **125**: 1808–17.
27. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* **11**: 791–6.
28. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. (2005) Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci U S A* **102**: 9294–9.
29. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., Mckeating J.A., Rice C.M. (2005) Complete replication of hepatitis C virus in cell culture. *Science* **309**: 623–6.
30. Yi M., Ma Y., Yates J., Lemon S.M. (2007) Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. *J Virol* **81**: 629–38.
31. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., Abid K., Negro F., Dreux M., Cosset F.L., Bartenschlager R. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. *Proc Natl Acad Sci U S A* **103**: 7408–13.
32. Gottwein J.M., Scheel T.K., Jensen T.B., Lademann J.B., Prentoe J.C., Knudsen M.L., Hoegh A.M., Bukh J. (2009) Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. *Hepatology* **49**: 364–77.
33. Yi M., Villanueva R.A., Thomas D.L., Wakita T., Lemon S.M. (2006) Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc Natl Acad Sci U S A* **103**: 2310–5.
34. Yi M., Lemon S.M. (2004) Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. *J Virol* **78**: 7904–15.
35. Aly H.H., Watashi K., Hijikata M., Kaneko H., Takada Y., Egawa H., Uemoto S., Shimotohno K. (2007) Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. *J Hepatol* **46**: 26–36.
36. Forns X., Bukh J. (1999) The molecular biology of hepatitis C virus. Genotypes and quasispecies. *Clin Liver Dis* **3**: 693–716, vii.
37. Ikeda M., Sugiyama K., Mizutani T., Tanaka T., Tanaka K., Sekihara H., Shimotohno K., Kato N. (1998) Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. *Virus Res* **56**: 157–67.
38. Chong T.W., Smith R.L., Hughes M.G., Camden J., Rudy C.K., Evans H.L., Sawyer R.G., Pruett T.L. (2006) Primary human hepatocytes in spheroid formation to study hepatitis C infection. *J Surg Res* **130**: 52–7.
39. Molina S., Castet V., Pichard-Garcia L., Wychowski C., Meurs E., Pascussi J.M., Sureau C., Fabre J.M., Sacunha A., Larrey D., Dubuisson J., Coste J., Mckeating J., Maurel P., Fournier-Wirth C. (2008) Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. *J Virol* **82**: 569–74.
40. Delgado J.P., Parouchev A., Allain J.E., Pennarun G., Gauthier L.R., Dutrillaux A.M., Dutrillaux B., Di Santo J., Capron F., Boussin F.D., Weber A. (2005) Long-term controlled immortalization of a primate hepatic progenitor cell line after Simian virus 40 T-Antigen gene transfer. *Oncogene* **24**: 541–51.
41. Chen W.H., Lai W.F., Deng W.P., Yang W.K., Lo W.C., Wu C.C., Yang D.M., Lai M.T., Lin C.T., Lin T.W., Yang C.B. (2006) Tissue

engineered cartilage using human articular chondrocytes immortalized by HPV-16 E6 and E7 genes. *J Biomed Mater Res A* **76**: 512–20.
42. Dimri G., Band H., Band V. (2005) Mammary epithelial cell transformation: insights from cell culture and mouse models. *Breast Cancer Res* **7**: 171–9.
43. Harms W., Rothamel T., Miller K., Harste G., Grassmann M., Heim A. (2001) Characterization of human myocardial fibroblasts immortalized by HPV16 E6–E7 genes. *Exp Cell Res* **268**: 252–61.
44. Shiga T., Shirasawa H., Shimizu K., Dezawa M., Masuda Y., Simizu B. (1997) Normal human fibroblasts immortalized by introduction of human papillomavirus type 16 (HPV-16) E6-E7 genes. *Microbiol Immunol* **41**: 313–9.
45. Akimov S.S., Ramezani A., Hawley T.S., Hawley R.G. (2005) Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells. *Stem Cells* **23**: 1423–33.
46. Watashi K., Inoue D., Hijikata M., Goto K., Aly H.H., Shimotohno K. (2007) Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. *J Biol Chem* **282**: 32765–72.
47. Murakami Y., Aly H.H., Tajima A., Inoue I., Shimotohno K. (2009) Regulation of the hepatitis C virus genome replication by miR-199a. *J Hepatol* **50**: 453–60.
48. Andrei G. (2006) Three-dimensional culture models for human viral diseases and antiviral drug development. *Antiviral Res* **71**: 96–107.
49. Aizaki H., Nagamori S., Matsuda M., Kawakami H., Hashimoto O., Ishiko H., Kawada M., Matsuura T., Hasumura S., Matsuura Y., Suzuki T., Miyamura T. (2003) Production and release of infectious hepatitis C virus from human liver cell cultures in the three-dimensional radial-flow bioreactor. *Virology* **314**: 16–25.
50. Mizumoto H., Ishihara K., Nakazawa K., Ijima H., Funatsu K., Kajiwara T. (2008) A new culture technique for hepatocyte organoid formation and long-term maintenance of liver-specific functions. *Tissue Eng Part C Methods* **14**: 167–75.
51. Funatsu K., Ijima H., Nakazawa K., Yamashita Y., Shimada M., Sugimachi K. (2001) Hybrid artificial liver using hepatocyte organoid culture. *Artif Organs* **25**: 194–200.
52. Mizumoto H., Aoki K., Nakazawa K., Ijima H., Funatsu K., Kajiwara T. (2008) Hepatic differentiation of embryonic stem cells in HF/organoid culture. *Transplant Proc* **40**: 611–3.
53. Aly H.H., Shimotohno K., Hijikata M. (2009) 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV. *Biochem Biophys Res Commun* **379**: 330–4.
54. Aly H.H., Qi Y., Atsuzawa K., Usuda N., Takada Y., Mizokami M., Shimotohno K., Hijikata M. (2009) Strain-dependent viral dynamics and virus-cell interactions in a novel in vitro system supporting the life cycle of blood-borne hepatitis C virus. *Hepatology* **50**: 689–96.
55. Nishimura-Sakurai Y., Sakamoto N., Mogushi K., Nagaie S., Nakagawa M., Itsui Y., Tasaka-Fujita M., Onuki-Karakama Y., Suda G., Mishima K., Yamamoto M., Ueyama M., Funaoka Y., Watanabe T., Azuma S., Sekine-Osajima Y., Kakinuma S., Tsuchiya K., Enomoto N., Tanaka H., Watanabe M. (2010) Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. *J Gastroenterol* **45**: 523–36.
56. Chockalingam K., Simeon R.L., Rice C.M., Chen Z. (2010) A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. *Proc Natl Acad Sci U S A* **107**: 3764–9.
57. Gastaminza P., Whitten-Bauer C., Chisari F.V. (2010) Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. *Proc Natl Acad Sci U S A* **107**: 291–6.
58. Rakic B., Sagan S.M., Noestheden M., Belanger S., Nan X., Evans C.L., Xie X.S., Pezacki J.P. (2006) Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. *Chem Biol* **13**: 23–30.
59. Bukh J. (2004) A critical role for the chimpanzee model in the study of hepatitis C. *Hepatology* **39**: 1469–75.
60. Heckel J.L., Sandgren E.P., Degen J.L., Palmiter R.D., Brinster R.L. (1990) Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. *Cell* **62**: 447–56.
61. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., Kneteman N.M. (2001) Hepatitis C virus replication in mice with chimeric human livers. *Nat Med* **7**: 927–33.
62. Tateno C., Yoshizane Y., Saito N., Kataoka M., Utoh R., Yamasaki C., Tachibana A., Soeno Y., Asahina K., Hino H., Asahara T., Yokoi T., Furukawa T., Yoshizato K. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. *Am J Pathol* **165**: 901–12.
63. Diamond M.S. (2009) Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. *J Interferon Cytokine Res* **29**: 521–30.
64. O'neill L.A., Bowie A.G. (2010) Sensing and signaling in antiviral innate immunity. *Curr Biol* **20**: R328–33.
65. Platanias L.C. (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. *Nat Rev Immunol* **5**: 375–86.
66. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* **41**: 1105–9.
67. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R., Poordad F., Lawitz E.J., Mccone J., Shiffman M.L., Galler G.W., Lee W.M., Reindollar R., King J.W., Kwo P.Y., Ghalib R.H., Freilich B., Nyberg L.M., Zeuzem S., Poynard T., Vock D.M., Pieper K.S., Patel K., Tillmann H.L., Noviello S., Koury K., Pedicone L.D., Brass C.A., Albrecht J.K., Goldstein D.B., Mchutchison J.G. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology* **139**: 120–9 e18.
68. Sumpter R., Jr., Loo Y.M. Foy E., Li K., Yoneyama M., Fujita T., Lemon S.M., Gale M., Jr. (2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. *J Virol* **79**: 2689–99.
69. Foy E., Li K., Sumpter R., Jr., Loo Y.M., Johnson C.L., Wang C., Fish P.M., Yoneyama M., Fujita T., Lemon S.M., Gale M., Jr. (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. *Proc Natl Acad Sci U S A* **102**: 2986–91.
70. Aly H.H., Oshiumi H., Shime H., Matsumoto M., Wakita T., Shimotohno K., Seya T. (2011) Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). *PLoS One* **6**: e21284.
71. Lin L.T., Noyce R.S., Pham T.N., Wilson J.A., Sisson G.R., Michalak T.I., Mossman K.L., Richardson C.D. (2010) Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. *J Virol* **84**: 9170–80.

J. Biochem. 2012;151(1):5–11 doi:10.1093/jb/mvr111

JB THE JOURNAL OF BIOCHEMISTRY

JB Review
Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I

Received July 11, 2011; accepted August 17, 2011; published online September 2, 2011

Hiroyuki Oshiumi*, Misako Matsumoto and Tsukasa Seya

Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku Sapporo 060-8638, Japan

*To whom correspondence should be addressed.
Tel: þ81-11-706-5056, Fax: þ81-11-706-7866.
E-mail: oshiumi@med.hokudai.ac.jp

RIG-I-like receptors, including RIG-I, MDA5 and LGP2, recognize cytoplasmic viral RNA. The RIG-I protein consists of N-terminal CARDs, central RNA helicase and C-terminal domains. RIG-I activation is regulated by ubiquitination. Three ubiquitin ligases target the RIG-I protein. TRIM25 and Riplet ubiquitin ligases are positive regulators of RIG-I and deliver the K63-linked polyubiquitin moiety to RIG-I CARDs and the C-terminal domain. RNF125, another ubiquitin ligase, is a negative regulator of RIG-I and mediates K48-linked polyubiquitination of RIG-I, leading to the degradation of the RIG-I protein by proteasomes. The K63-linked polyubiquitin chains of RIG-I are removed by a deubiquitin enzyme, CYLD. Thus, CYLD is a negative regulator of RIG-I. Furthermore, TRIM25 itself is regulated by ubiquitination. HOIP and HOIL proteins are ubiquitin ligases and are also known as linear ubiquitin assembly complexes (LUBACs). The TRIM25 protein is ubiquitinated by LUBAC and then degraded by proteasomes. The splice variant of RIG-I encodes a protein that lacks the first CARD of RIG-I, and the variant RIG-I protein is not ubiquitinated by TRIM25. Therefore, ubiquitin is the key regulator of the cytoplasmic viral RNA sensor RIG-I.

Keywords: RIG-I/type I interferon/ubiquitin/virus.

Abbreviations: CARD, caspase activation and recruitment domain; CTD, C-terminal domain; dsRNA, double-stranded RNA; RLR, RIG-I-like receptor; pDC, plasmacytoid dendritic cell; cDC, conventional dendritic cell; MEF, mouse embryonic fibroblast cell; BM, bone-marrow; Mf, macrophage; IFN, interferon; ISG, interferon-stimulated gene; TRIM, tripartite motif; RNF, RING finger.

Recognition of viral RNA

Type I interferons (IFNs) are inflammatory cytokines that possess strong anti-viral activity. During viral infection, type I IFNs are produced from dendritic cells (DC), macrophages (Mf) and fibroblast cells (Fig. 1A). Viral RNA is mainly recognized by Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs). TLRs are type I transmembrane proteins. TLR3, 7 and 8, which are members of the TLR family, are localized to endosomes, and are responsible for the recognition of viral RNA (1). RLRs are DExD/H box RNA helicases and recognize viral RNA in the cytoplasmic region (Fig. 1B). There are three members of the RLR family: RIG-I, MDA5 and LGP2. RIG-I has the ability to recognize various types of viruses, and MDA5 mainly recognizes picornaviruses (2). LGP2 promotes RIG-I and MDA5-mediated signalling (3).

A cytoplasmic sensor for the detection of viral RNA

RIG-I, a cytoplasmic sensor for viral RNA, is induced by viral infection, polyIC and type I IFN stimulation (4). This protein is composed of two N-terminal caspase recruitment domains (CARDs), a central DExD/H box helicase/ATPase domain and a C-terminal regulatory domain (CTD) (Fig. 2). N-terminal CARDs are responsible for the binding to the adaptor molecule IPS-1/MAVS/VISA/Cardif, which is located on the outer membrane of the mitochondria (5 8). In the absence of viral RNA, RIG-I CTD represses the interaction between RIG-I CARDs and IPS-1 CARD (9). RIG-I CTD recognizes the 5^{0} triphosphate of short double-stranded RNA, leading to multimerization of RIG-I and IPS-1 (10 13). IPS-1 triggers signaling to induce type I IFN and other inflammatory cytokines through STING (also called MITA) protein, which is localized to the endoplasmic reticulum or the mitochondria (14 17). STING then activates transcription factors, such as IRF-3, IRF-7 and NF-kB (15, 18).

Knockout of RIG-I abrogates the production of type I IFNs and inflammatory cytokines from mouse embryonic fibroblasts (MEFs), conventional DC and Mfs in response to viral infections, including infections caused by vesicular stomatitis virus (VSV), Sendai virus (SeV), influenza A virus, Newcastle disease virus, hepatitis C virus and Japanese encephalitis virus (2, 19). However, RIG-I is not necessary for the production of type I IFNs by plasmacytoid dendritic cells (pDCs), which are strong inducers of type I IFNs in vivo (19). In pDCs, TLR7 is responsible for the detection of viral RNA (20). In addition, knockout of IPS-1 and STING inhibits the production of type I IFNs from MEFs, Mfs and cDCs, but not from pDCs (15 18). Once type I IFNs are produced from these cells, IFN production is secondly amplified via the IFNAR (21). The deficiency of the RIG-I-dependent pathway causes a reduction in early type I IFN production in vivo but shows only a marginal effect on late type I IFN production (15 18). Knockout of RIG-I increases the



Fig. 1 Production of type I IFN in response to viral infection. (A) Type I IFN is a cytokine that possesses strong anti-viral activity. Type I IFN is produced from fibroblast cells, cDC, pDC and Mf in response to viral infection. (B) TLR3, 7 and 8 are localized to endosomes and are responsible for the recognition of viral RNA. Viral RNA in the cytoplasmic region is recognized by RIG-I and MDA5, leading to the activation of the adaptor molecule IPS-1. IPS-1 triggers the signal to induce type I IFNs. Type I IFNs binds to an IFN receptor, IFNAR, leading to the activation of anti-viral factors, such as PKR and RNaseL.

mortality due to viral infections (2, 19). Thus, RIG-I-dependent pathways are necessary for efficient early type I IFN production and are required for protection against viral infections (18).

TRIM25 ubiquitin ligase is a positive factor for the RIG-I activation

During viral infection, the RIG-I protein has a modified form of ubiquitin. TRIM25 (also called Efp)



Fig. 2 Domain structures of TRIM25, Riplet, RNF125 and RIG-I. TRIM25 consists of RING finger, B-box, coiled-coil, PRY and SPRY domains. Riplet is similar to TRIM25 and consists of RING-finger, PRY and SPRY domains. RNF125 consists of RING-finger and two zinc-finger domains. Three proteins mediate the polyubiquitination of RIG-I. RIG-I consists of two N-terminal CARDs, central RNA helicase and CTDs.

is a ubiquitin ligase (22, 23), and its domain structure is described in Fig. 2. This protein interacts with the first CARD of RIG-I (22, 24). T55I mutation of the first CARD of RIG-I is found in RIG-I-deficient HuH7.5 cells. T55 of RIG-I is critical for the interaction between TRIM25 and RIG-I (9, 24, 25). Gack et al. detected the polyubiquitination of the K99, K169, K172, K181, K190 and K193 residues of RIG-I CARDs by mass spectrometry analysis (22), and the K172R mutation alone causes a near-complete loss of the polyubiquitination of RIG-I CARDs (22). TRIM25 delivers the K63-linked polyubiquitin moiety to the K172 residue of the second CARD of RIG-I, leading to efficient interaction with IPS-1/MAVS/VISA/Cardif (22, 24). On the other hand, Zeng et al. reported another mechanism of the activation of RIG-I by ubiquitin. They reconstituted RIG-I pathway in vitro and showed that RIG-I CARDs sense unanchored polyubiquitin chains mediated by TRIM25, and the binding of RIG-I CARDs to the unanchored polyubiquitin chains leads to the activation of RIG-I (26). Knockout of TRIM25 abrogates IFN-b production from MEF in response to viral infection (22). Thus, ubiquitination or polyubiquitin binding is essential for the activation of RIG-I (Fig. 2).

The expression of a splice variant of RIG-I mRNA is robustly up-regulated upon viral infection (24). This splice variant encodes a protein that lacks the first 36 80 amino acid region within the first CARD of RIG-I; therefore, the RIG-I splice variant (RIG-I SV) protein loses TRIM25 binding, CARD ubiquitination and downstream signalling ability (Fig. 3) (24). RIG-I SV inhibits the multimerization of the wild-type RIG-I protein and IPS-1 interaction and shows a dominant negative effect on the RIG-I-mediated anti-viral IFN response (24). Thus, RIG-I SV acts as the off switch regulator of its own signalling pathway (24).

In addition to the IPS-1 adaptor molecule, RIG-I also binds to the inflammasome adaptor apoptosis-associated speck-like protein containing a CARD domain (ASC), also known as Pycard, in response to viral infection (27). ASC activates caspase-1, leading to the proteolytic processing of pro-IL-1b into mature, bioactive IL-1b (28). TRIM25 activity is dispensable for caspase-1 activation through ASC (27). Thus, RIG-I polyubiquitination by TRIM25 is dispensable for ASC inflammasome adaptor activation (27).



Fig. 3 Regulation of RIG-I by the ubiquitin chain. RIG-I binds to viral RNA together with other cofactors, such as DDX3. After the recognition of viral RNA, RIG-I changes its conformation and harbours K63-linked polyubiquitination by TRIM25 and Riplet. Polyubiquitination causes the activation of IPS-1, leading to the production of type I IFN. CYLD, a deubiquitin enzyme, removes the polyubiquitin chain of RIG-I. CK2 and other unknown kinase phosphorylate RIG-I, and the phosphorylated RIG-I protein is not polyubiquitinated by TRIM25. In addition, splice variant RIG-I (SV RIG-I) is not polyubiquitinated by TRIM25, and the SV RIG-I protein acts as a dominant negative form. RNF125 mediates the K48-linked polyubiquitinatioin of RIG-I, which causes the degradation of RIG-I by proteasomes. The LUBAC protein complex suppresses TRIM25 function by mediating the head-to-tail polyubiquitination of TRIM25.

However, RIG-I polyubiquitination is essential for NF-kB activation by RIG-I, which is required for IL-1b mRNA expression; thus, knockout of TRIM25 reduces the production of mature IL-1b (4, 19, 27).

Riplet ubiquitin ligase is essential for the activation of RIG-I

Riplet (also called Reul or RNF135) was isolated by yeast two-hybrid screening to isolate RIG-I CTD binding proteins (29). The Riplet protein is composed of N-terminal RING finger, C-terminal SPRY and PRY domains, and is similar to TRIM25 (Fig. 2). However, this protein lacks B-box, which is a typical feature of TRIM family proteins. Thus, the protein does not belong to the TRIM family. Riplet expression is observed in various tissues and cells such as DC, Mfs and MEF (29, 30). Hu et al. (31) detected endogenous Riplet protein in human DC lysates. Riplet expression is induced in mouse bone marrow-derived DCs (BM-DCs) by polyIC stimulation, which is a double-stranded RNA analog; however, its expression is not changed in human fibroblast and HeLa cells (29).

The Riplet protein physically interacts with RIG-I CTD, and in some experimental conditions, it binds to RIG-I CARDs (29, 32). The Riplet C-terminal region is responsible for this binding. Riplet mediates K63-linked polyubiquitination of RIG-I CTD, leading to the activation of RIG-I (Fig. 3) (29). The five CTD lysine residues at 849, 851, 888, 907 and 909 are important for the polyubiquitination and activation of RIG-I (29, 30). In contrast, Gao et al. (32) reported that Riplet mediates K63-linked polyubiquitination of K154, K164 and K172 of RIG-I CARDs in their experimental conditions (Fig. 3).

In some strain backgrounds, RIG-I-deficient mice are embryonic lethal, but Riplet knockout mice are born at expected Mendelian ratios from Riplet$^{b/}$ mice (19, 30, 33). Moreover, the development of DCs and Mfs is also normal in Riplet-deficient mice (30). Douglas et al. (30, 34) reported that Riplet/RNF135 haploinsufficiency causes an overgrowth syndrome and learning disabilities in human: however, knockout of the Riplet gene in mice does not cause any apparent defects with regard to development. Knockout of Riplet severely reduces the production of type I IFN and abrogates the activation of RIG-I and RIG-I CTD polyubiquitination (30). Riplet knockout mice are more susceptible to VSV infection than wild-type mice. As IPS-1 and STING, Riplet is necessary for efficient, early type I IFN production in vivo, but it is dispensable for late type I IFN productions (30). This indicates the essential role that Riplet plays in the RIG-I-dependent innate immune response against RNA virus infection. Genetic evidence shows that knockout of either Riplet or TRIM25 destroyed the RIG-I-dependent innate immune response; therefore, both ubiquitin ligases are required for the activation of RIG-I in response to RNA virus infection (22, 30). RLR pathways contribute to type I IFN expression in response to cytoplasmic DNA (35 37). However, Riplet-independent type I IFN expression pathway in response to cytoplasmic DNA exists in MEF (30).

Ubiquitin ligases target several proteins. For example, TRIM25 targets the proteolysis of 14-3-3 s, a negative cell cycle regulator that causes G2 arrest, and thus, promotes breast tumour growth (23). Proteome analysis reveals that Riplet binds to the TRK-fused gene (TFG), which is a target of chromosome translocation in lymphoma (38 40). Pasmant et al. (41) reported that the Riplet/RNF135 gene is down-regulated in tumour Schwann cells from malignant peripheral nerve sheath tumours, and their study suggested the involvement of Riplet/RNF135 in an increased risk of malignancy observed in NF1 microdeletion patients. Thus, it is possible that Riplet targets not only RIG-I but also other proteins.

Negative regulators of RIG-I

The RNF125 (also called TRAC1) protein possesses a RING finger domain and functions as a ubiquitin ligase (42). Arimoto et al. (43) isolated RNF125 by yeast two-hybrid screening to obtain the protein that binds to UbcH8, which is an E2 ubiquitin-conjugating enzyme, and found that RNF125 also binds to RIG-I. Unlike Riplet and TRIM25, RNF125 ubiquitin ligase mediates K48-, but not K63-linked polyubiquitination of RIG-I, leading to the degradation of RIG-I by proteasomes (Fig. 3) (43). UbcH5c is possibly an E2 enzyme, which cooperates with RNF125, and UbcH8 acts as a negative factor in the RNF125-mediated polyubiquitination of RIG-I (43, 44). Furthermore, RNF125 ubiquitinates MDA5, a member of RLRs, and the expression of RNF125 impairs MDA5-mediated signalling (43). RNF125 expression is induced by type I IFN and polyIC treatment. The increase in RNF125 mRNA expression correlates temporally with the decrease in RIG-I expression (43). Knockdown of RNF125 increases the type I IFN expression in response to viral infection (43). Since RNF125 is enhanced by type I IFN, the function of RNF125 constitutes a negative regulatory loop circuit for type I IFN production.

CYLD is a deubiquitinase that cleaves the K63-linked polyubiquitin chain. This protein acts as a negative regulator of NF-kB and Jun N-terminal kinase signalling pathways by cleaving the K63-linked polyubiquitin chains of NEMO, TRAF2 and BCL3 (45 48). Friedman et al. (49) performed a microarray analysis and found that the expression profile of RIG-I is correlated with that of CYLD. Moreover, they found that the CYLD protein physically interacts with RIG-I, TBK1 and IKK", and deubiquitinates these proteins. CYLD inhibits SeV-induced type I IFN production. Thus, it is expected that CYLD attenuates the establishment of an anti-viral state (Fig. 3).

There are host and viral negative regulators for TRIM25. HOIL-1L and HOIP are members of the RING-IBR-RING (RBR) E3 ubiquitin ligase family and form complexes (50). HOIL-1L and HOIP form ubiquitin polymers through the linkage between the C- and N-termini of the ubiquitin molecules in order to assemble a head-to-tail linear polyubiquitin chain; thus,

the protein complex is designated as LUBAC (linear ubiquitin assembly complex) (50). LUBAC has the ability to induce polyubiquitination of TRIM25; it specifically suppresses TRIM25-mediated RIG-I ubiquitination by inducing TRIM25 degradation and inhibiting TRIM25 interaction with RIG-I (Fig. 3) (51). Excessive production of IFNs or inflammatory cytokines is destructive rather than protective; thus, an absolute regulation of the immune signalling pathway is essential for a successful immune response against viral infections. HOIL-1L- and HOIP-mediated suppression of TRIM25 would be important for the absolute regulation of an immune response (51).

Viruses have evolved sophisticated mechanisms to evade the host IFN system. There are several virus-encoded IFN antagonists that inhibit host innate anti-viral responses. NS1 of the influenza A virus is one of the IFN antagonists (52, 53). It sequestrates viral dsRNA from cellular sensors including RIG-I (52). In addition, it interacts with the coiled-coil region of TRIM25 and blocks TRIM25 multimerization and RIG-I CARD polyubiquitination (54).

Perspectives

Several ubiquitin-like proteins (UBLs) exist. ISG15 is a UBL and is induced in response to viral infection (55). Several anti-viral proteins are modified by ISG15, including RIG-I (44, 55). UbcH8 is an E2 enzyme that promotes ISG15 conjugation to RIG-I (44). However, ISG15 knockout mice do not either reduce immunological functions or decrease anti-viral activity (56). Thus, the physiological role of ISG15 conjugation to RIG-I remains unknown.

In addition, the RIG-I protein is modified by phosphorylation. The T170 residue of RIG-I is phosphorylated under normal conditions, and phosphorylation is reduced after SeV infection (24). Phosphorylation of RIG-I CARDs inhibits the TRIM25-mediated polyubiquitination (Fig. 3). Thus, Gack et al. suggested that dephosphorylation of RIG-I permits the TRIM25 binding and TRIM25-mediated polyubiquitination of RIG-I, allowing RIG-I to form a stable complex with IPS-1 in order to trigger an IFN-mediated anti-viral innate immune response. However, the kinase and phosphatase that target RIG-I N-terminal CARDs are still unknown. In addition to RIG-I CARDs, RIG-I CTD is regulated by phosphorylation. In resting cells, casein kinase II (CK2) phosphorylates T770, and S854 and S855 (57). The phosphorylation of RIG-I CTD suppresses the RIG-I-mediated signalling (Fig. 3) (57). Following viral infection, phosphatases cause dephosphorylation of the RIG-I CTD, leading to the activation of RIG-I-mediated signalling (57).

RIG-I requires several cofactors. High mobility group box proteins are required for the RIG-I to recognize viral RNA (58). DDX3 and DDX60 are non-RLR helicases that are involved in RLR signallings, and play pivotal roles in RIG-I-mediated signalling (Fig. 3) (59 62). It remains to be determined whether the post-translational modification of RIG-I affects the interaction with those co-factors.

Riplet ubiquitinates RIG-I CTD. The molecular mechanism of how the Riplet-dependent polyubiquitination of RIG-I CTD triggers the downstream signalling remains to be determined yet. RIG-I CTD has two functions. In the absence of viral RNA, RIG-I CTD suppresses the activation of RIG-I CARDs. Following viral infection, RIG-I CTD binds to viral RNA, leading to the conformational changes and ultimately removal of the suppression. It is possible that CTD polyubiquitination affects both functions of RIG-I CTD.

Funding
Grants-in-Aid from the Ministry of Education, Science, and Culture and the Ministry of Health, Labor and Welfare of Japan.

Conflict of Interest
None declared.

References

1. Takeuchi, O. and Akira, S. (2010) Pattern recognition receptors and inflammation. Cell 140, 805 820
2. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C. S., Reis e Sousa, C., Matsuura, Y., Fujita, T., and Akira, S. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101 105
3. Satoh, T., Kato, H., Kumagai, Y., Yoneyama, M., Sato, S., Matsushita, K., Tsujimura, T., Fujita, T., Akira, S., and Takeuchi, O. (2010) LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc. Natl Acad. Sci. USA 107, 1512 1517
4. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., and Fujita, T. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730 737
5. Xu, L.G., Wang, Y.Y., Han, K.J., Li, L.Y., Zhai, Z., and Shu, H.B. (2005) VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 19, 727 740
6. Seth, R.B., Sun, L., Ea, C.K., and Chen, Z.J. (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122, 669 682
7. Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., and Tschopp, J. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167 1172
8. Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J., Takeuchi, O., and Akira, S. (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981 988
9. Saito, T., Hirai, R., Loo, Y.M., Owen, D., Johnson, C.L., Sinha, S.C., Akira, S., Fujita, T., and Gale, M. Jr (2007) Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl. Acad. Sci. USA 104, 582 587
10. Schmidt, A., Schwerd, T., Hamm, W., Hellmuth, J.C., Cui, S., Wenzel, M., Hoffmann, F.S., Michallet, M.C., Besch, R., Hopfner, K.P., Endres, S., and Rothenfusser,

S. (2009) 5′-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc. Natl. Acad. Sci. USA 106, 12067 12072
11. Myong, S., Cui, S., Cornish, P.V., Kirchhofer, A., Gack, M.U., Jung, J.U., Hopfner, K.P., and Ha, T. (2009) Cytosolic viral sensor RIG-I is a 5′-triphosphate-dependent translocase on double-stranded RNA. Science 323, 1070 1074
12. Pichlmair, A., Schulz, O., Tan, C.P., Naslund, T.I., Liljestrom, P., Weber, F., and Reis e Sousa, C. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997 1001
13. Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.K., Schlee, M., Endres, S., and Hartmann, G. (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994 997
14. Zhong, B., Yang, Y., Li, S., Wang, Y.Y., Li, Y., Diao, F., Lei, C., He, X., Zhang, L., Tien, P., and Shu, H.B. (2008) The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29, 538 550
15. Ishikawa, H. and Barber, G.N. (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674 678
16. Sun, Q., Sun, L., Liu, H.H., Chen, X., Seth, R.B., Forman, J., and Chen, Z.J. (2006) The specific and essential role of MAVS in antiviral innate immune responses. Immunity 24, 633 642
17. Kumar, H., Kawai, T., Kato, H., Sato, S., Takahashi, K., Coban, C., Yamamoto, M., Uematsu, S., Ishii, K.J., Takeuchi, O., and Akira, S. (2006) Essential role of IPS-1 in innate immune responses against RNA viruses. J. Exp. Med. 203, 1795 1803
18. Ishikawa, H., Ma, Z., and Barber, G.N. (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788 792
19. Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., and Akira, S. (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19 28
20. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S., and Reis e Sousa, C. (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529 1531
21. Honda, K., Takaoka, A., and Taniguchi, T. (2006) Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349 360
22. Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., and Jung, J.U. (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916 920
23. Urano, T., Saito, T., Tsukui, T., Fujita, M., Hosoi, T., Muramatsu, M., Ouchi, Y., and Inoue, S. (2002) Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417, 871 875
24. Gack, M.U., Kirchhofer, A., Shin, Y.C., Inn, K.S., Liang, C., Cui, S., Myong, S., Ha, T., Hopfner, K.P., and Jung, J.U. (2008) Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc. Natl. Acad. Sci. USA 105, 16743 16748
25. Sumpter, R. Jr, Loo, Y.M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S.M., and Gale, M. Jr (2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79, 2689 2699
26. Zeng, W., Sun, L., Jiang, X., Chen, X., Hou, F., Adhikari, A., Xu, M., and Chen, Z.J. (2010) Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 141, 315 330
27. Poeck, H., Bscheider, M., Gross, O., Finger, K., Roth, S., Rebsamen, M., Hannesschlager, N., Schlee, M., Rothenfusser, S., Barchet, W., Kato, H., Akira, S., Inoue, S., Endres, S., Peschel, C., Hartmann, G., Hornung, V., and Ruland, J. (2010) Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat. Immunol. 11, 63 69
28. Yu, H.B. and Finlay, B.B. (2008) The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe 4, 198 208
29. Oshiumi, H., Matsumoto, M., Hatakeyama, S., and Seya, T. (2009) Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection. J. Biol. Chem. 284, 807 817
30. Oshiumi, H., Miyashita, M., Inoue, N., Okabe, M., Matsumoto, M., and Seya, T. (2010) The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection. Cell Host Microbe 8, 496 509
31. Hu, J., Nistal-Villan, E., Voho, A., Ganee, A., Kumar, M., Ding, Y., Garcia-Sastre, A., and Wetmur, J.G. (2010) A common polymorphism in the caspase recruitment domain of RIG-I modifies the innate immune response of human dendritic cells. J. Immunol. 185, 424 432
32. Gao, D., Yang, Y.K., Wang, R.P., Zhou, X., Diao, F.C., Li, M.D., Zhai, Z.H., Jiang, Z.F., and Chen, D.Y. (2009) REUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acid-inducible gene-I. PLoS One 4, e5760
33. Wang, Y., Zhang, H.X., Sun, Y.P., Liu, Z.X., Liu, X.S., Wang, L., Lu, S.Y., Kong, H., Liu, Q.L., Li, X.H., Lu, Z.Y., Chen, S.J., Chen, Z., Bao, S.S., Dai, W., and Wang, Z.G. (2007) Rig-I-/- mice develop colitis associated with downregulation of G alpha i2. Cell Res 17, 858 868
34. Douglas, J., Cilliers, D., Coleman, K., Tatton-Brown, K., Barker, K., Bernhard, B., Burn, J., Huson, S., Josifova, D., Lacombe, D., Malik, M., Mansour, S., Reid, E., Cormier-Daire, V., Cole, T., and Rahman, N. (2007) Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. Nat. Genet. 39, 963 965
35. Choi, M.K., Wang, Z., Ban, T., Yanai, H., Lu, Y., Koshiba, R., Nakaima, Y., Hangai, S., Savitsky, D., Nakasato, M., Negishi, H., Takeuchi, O., Honda, K., Akira, S., Tamura, T., and Taniguchi, T. (2009) A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA. Proc. Natl. Acad. Sci. USA 106, 17870 17875
36. Chiu, Y.H., Macmillan, J.B., and Chen, Z.J. (2009) RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138, 576 591
37. Ablasser, A., Bauernfeind, F., Hartmann, G., Latz, E., Fitzgerald, K.A., and Hornung, V. (2009) RIG-I-

dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 10, 1065 1072

38. Chase, A., Ernst, T., Fiebig, A., Collins, A., Grand, F., Erben, P., Reiter, A., Schreiber, S., and Cross, N.C. (2010) TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica 95, 20 26
39. Suzuki, H., Fukunishi, Y., Kagawa, I., Saito, R., Oda, H., Endo, T., Kondo, S., Bono, H., Okazaki, Y., and Hayashizaki, Y. (2001) Protein protein interaction panel using mouse full-length cDNAs. Genome Res. 11, 1758 1765
40. Hernandez, L., Pinyol, M., Hernandez, S., Bea, S., Pulford, K., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D.Y., Delsol, G., and Campo, E. (1999) TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94, 3265 3268
41. Pasmant, E., Masliah-Planchon, J., Levy, P., Laurendeau, I., Ortonne, N., Parfait, B., Valeyrie-Allanore, L., Leroy, K., Wolkenstein, P., Vidaud, M., Vidaud, D., and Bieche, I. (2011) Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Mol. Med. 17, 79 87
42. Zhao, H., Li, C.C., Pardo, J., Chu, P.C., Liao, C.X., Huang, J., Dong, J.G., Zhou, X., Huang, Q., Huang, B., Bennett, M. K., Molineaux, S.M., Lu, H., Daniel-Issakani, S., Payan, D.G., and Masuda, E.S. (2005) A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell activation. J. Immunol. 174, 5288 5297
43. Arimoto, K., Takahashi, H., Hishiki, T., Konishi, H., Fujita, T., and Shimotohno, K. (2007) Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc. Natl. Acad. Sci. USA 104, 7500 7505
44. Arimoto, K., Konishi, H., and Shimotohno, K. (2008) UbcH8 regulates ubiquitin and ISG15 conjugation to RIG-I. Mol. Immunol. 45, 1078 1084
45. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., and Mosialos, G. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793 796
46. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., and Courtois, G. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801 805
47. Brummelkamp, T.R., Nijman, S.M., Dirac, A.M., and Bernards, R. (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424, 797 801
48. Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A., and Fassler, R. (2006) Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125, 665 677
49. Friedman, C.S., O'Donnell, M.A., Legarda-Addison, D., Ng, A., Cardenas, W.B., Yount, J.S., Moran, T.M., Basler, C.F., Komuro, A., Horvath, C.M., Xavier, R., and Ting, A.T. (2008) The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 9, 930 936
50. Kirisako, T., Kamei, K., Murata, S., Kato, M., Fukumoto, H., Kanie, M., Sano, S., Tokunaga, F., Tanaka, K., and Iwai, K. (2006) A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 25, 4877 4887
51. Inn, K.S., Gack, M.U., Tokunaga, F., Shi, M., Wong, L.Y., Iwai, K., and Jung, J.U. (2011) Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. Mol. Cell 41, 354 365
52. Diebold, S.S., Montoya, M., Unger, H., Alexopoulou, L., Roy, P., Haswell, L.E., Al-Shamkhani, A., Flavell, R., Borrow, P., and Reis e Sousa, C. (2003) Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424, 324 328
53. Garcia-Sastre, A., Egorov, A., Matassov, D., Brandt, S., Levy, D.E., Durbin, J.E., Palese, P., and Muster, T. (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324 330
54. Gack, M.U., Albrecht, R.A., Urano, T., Inn, K.S., Huang, I.C., Carnero, E., Farzan, M., Inoue, S., Jung, J.U., and Garcia-Sastre, A. (2009) Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5, 439 449
55. Zhao, C., Denison, C., Huibregtse, J.M., Gygi, S., and Krug, R.M. (2005) Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. USA 102, 10200 10205
56. Knobeloch, K.P., Utermohlen, O., Kisser, A., Prinz, M., and Horak, I. (2005) Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Mol. Cell Biol. 25, 11030 11034
57. Sun, Z., Ren, H., Liu, Y., Teeling, J.L., and Gu, J. (2011) Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response. J. Virol. 85, 1036 1047
58. Yanai, H., Ban, T., Wang, Z., Choi, M.K., Kawamura, T., Negishi, H., Nakasato, M., Lu, Y., Hangai, S., Koshiba, R., Savitsky, D., Ronfani, L., Akira, S., Bianchi, M. E., Honda, K., Tamura, T., Kodama, T., and Taniguchi, T. (2009) HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462, 99 103
59. Oshiumi, H., Sakai, K., Matsumoto, M., and Seya, T. (2010) DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta-inducing potential. Eur. J. Immunol. 40, 940 948
60. Soulat, D., Burckstummer, T., Westermayer, S., Goncalves, A., Bauch, A., Stefanovic, A., Hantschel, O., Bennett, K.L., Decker, T., and Superti-Furga, G. (2008) The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J. 27, 2135 2146
61. Schroder, M., Baran, M., and Bowie, A. G. (2008) Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J. 27, 2147 2157
62. Miyashita, M., Oshiumi, H., Matsumoto, M., and Seya, T. (2011) DDX60, a DExD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol. Cell Biol. 31, 3802 3819

THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 12, pp. 10702–10711, March 25, 2011

Raftlin Is Involved in the Nucleocapture Complex to Induce Poly(I:C)-mediated TLR3 Activation*[S]

Received for publication, September 15, 2010, and in revised form, January 23, 2011 Published, JBC Papers in Press, January 25, 2011, DOI 10.1074/jbc.M110.185793

Ayako Watanabe[‡], Megumi Tatematsu[‡], Kazuko Saeki[§], Sachiko Shibata[¶], Hiroaki Shime[‡], Akihiko Yoshimura[‖], Chikashi Obuse[¶], Tsukasa Seya[‡], and Misako Matsumoto[‡1]

From the [‡]Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, the [§]Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, the [¶]Division of Molecular Life Science, Graduate School of Life Science, Hokkaido University, Sapporo 001-0021, and the [‖]Department of Microbiology and Immunology, School of Medicine, Keio University, Tokyo 160-8582, Japan

The double-stranded RNA analog, poly(I:C), extracellularly activates both the endosomal Toll-like receptor (TLR) 3 and the cytoplasmic RNA helicase, melanoma differentiation-associated gene 5, leading to the production of type I interferons (IFNs) and inflammatory cytokines. The mechanism by which extracellular poly(I:C) is delivered to TLR3-positive organelles and the cytoplasm remains to be elucidated. Here, we show that the cytoplasmic lipid raft protein, Raftlin, is essential for poly(I:C) cellular uptake in human myeloid dendritic cells and epithelial cells. When Raftlin was silenced, poly(I:C) failed to enter cells and induction of IFN-β production was inhibited. In addition, cellular uptake of B-type oligodeoxynucleotide that shares its uptake receptor with poly(I:C) was suppressed in Raftlin knockdown cells. Upon poly(I:C) stimulation, Raftlin was translocated from the cytoplasm to the plasma membrane where it colocalized with poly(I:C), and thereafter moved to TLR3-positive endosomes. Thus, Raftlin cooperates with the uptake receptor to mediate cell entry of poly(I:C), which is critical for activation of TLR3.

Polyriboinosinic:polyribocytidylic acid (poly(I:C)),[2] a synthetic double-stranded RNA (dsRNA), has been used as a potent type I interferon (IFN-α/β) inducer in both *in vitro* and *in vivo* studies since the discovery of anti-viral activity of type I IFNs (1–3). Many types of cells including fibroblasts, epithelial cells, and myeloid dendritic cells (DCs), produce IFN-β upon stimulation with poly(I:C). Studies have demonstrated that extracellular poly(I:C) is recognized by Toll-like receptor (TLR) 3 and cytoplasmic RNA helicase, melanoma differentiation-associated gene 5 (MDA5), and induces innate immune responses including the production of type I IFNs and inflammatory cytokines (4–8). More recently, experimental evidence has accumulated that poly(I:C) acts as an adjuvant that enhances antibody production, natural killer cell activation, and cytotoxic T lymphocyte induction through the activation of TLR3 and/or MDA5 (9–15).

Human TLR3 localizes to the endosomal compartments in myeloid DCs, whereas it localizes to both the cell surface and endosomes of fibroblasts, macrophages, and epithelial cells (5, 16, 17). TLR3 signaling arises from an intracellular compartment in both cell types and requires endosomal maturation. After dsRNA recognition, endosomal TLR3 recruits an adaptor molecule, *i.e.* Toll-IL-1 receptor domain-containing adaptor molecule-1 (TICAM-1, also called TRIF) that activates the NF-κB, IRF-3, and AP-1 transcription factors, leading to IFN-β production (18, 19). Also, extracellular poly(I:C) is sensed by MDA5 in the cytoplasm, resulting in the activation of IRF-3 and NF-κB via the mitochondrial outer membrane protein IPS-1 (also called MAVS, Cardif, or VISA) (20–23). However, the mechanism by which poly(I:C) is delivered from the extracellular fluid to the intracellular dsRNA sensors remains unresolved.

A recent study showed that CD14 directly binds to poly(I:C) and mediates poly(I:C) cellular uptake (24). Bone marrow-derived macrophages from CD14-deficient mice exhibited impaired, but not completely diminished, responses to poly(I:C). Also, a class A scavenger receptor was identified as a cell surface receptor for poly(I:C) in human epithelial cells, although the response of poly(I:C) was only partially impaired in scavenger receptor A-deficient mice (25). These results suggest that an unidentified cell surface molecule mediates cell entry of poly(I:C). Indeed, we and others demonstrated that poly(I:C) is internalized into CD14-negative human myeloid DCs and HEK293 cells via clathrin-dependent endocytosis, and B- and C-type oligodeoxynucleotides (ODNs) share the uptake receptor with poly(I:C) (26–28).

In this study, we isolated poly(I:C)-binding proteins from CD14-negative cell lysates by sequential affinity chromatography with poly(U)- and poly(I:C)-Sepharose and subjected them to mass spectrometric analysis. Among the proteins identified, we selected several proteins that exhibited a transmembrane domain or a membrane-anchoring motif and examined whether they were involved in poly(I:C)-induced TLR3-mediated signaling. We found that Raftlin, a major lipid raft protein

* This work was supported in part by grants-in-aid from the Ministry of Education, Science, and Culture, the Ministry of Health, Labor, and Welfare of Japan, and the Akiyama Foundation, NorthTec Foundation, Yakult Foundation, and the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, MEXT.

[S] The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1–S3 and Figs. S1–S4.

[1] To whom correspondence should be addressed. Tel.: 81-11-706-6056; Fax: 81-11-706-7866; E-mail: matumoto@pop.med.hokudai.ac.jp.

[2] The abbreviations used are: poly(I:C), polyriboinosinic:polyribocytidylic acid; 4F2, 4F2 cell-surface antigen heavy chain; DCs, dendritic cells; BMDC, bone marrow-derived DC; CTXB, cholera toxin subunit B; MDA5, melanoma differentiation-associated gene 5; MβCD, methyl-β-cyclodextrin; MoDC, monocyte-derived immature DC; ODN, oligodeoxynucleotide; TICAM-1, Toll-IL-1 receptor-containing adaptor molecule-1; TLR, Toll-like receptor.

expressed by B cells, plays a critical role in poly(I:C) cellular uptake in human myeloid DCs and epithelial cells.

EXPERIMENTAL PROCEDURES

Cell Culture and Reagents—Human B cell lines Raji, BALL-1, and Namalwa were obtained from the Riken Cell Bank (Tukuba, Japan) and maintained in RPMI 1640 supplemented with 10% heat-inactivated FCS (BioSource Intl., Inc.) and antibiotics. HEK293 cells were obtained from Sumitomo Pharmaceuticals Co., Ltd. (Osaka, Japan) and maintained in Dulbecco's modified Eagle's medium low glucose (Invitrogen) supplemented with 10% heat-inactivated FCS and antibiotics. HeLa cells were kindly provided by Dr. T. Fujita (Kyoto University) and maintained in Eagle's minimal essential medium (Nissui, Tokyo, Japan) supplemented with 1% L-glutamine and 10% heat-inactivated FCS. Human monocyte-derived immature DCs (MoDCs) were generated from $CD14^+$ monocytes by culturing for 6 days in the presence of 500 units/ml of granulocyte-macrophage colony-stimulating factor and 100 units/ml of IL-4 (PeproTech). Bone marrow-derived DCs (BMDCs) were prepared as described (10). Polymyxin B, 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI), saponin, and methyl-β-cyclodextrin (MβCD) were purchased from Sigma. Poly(I:C) was from Amersham Biosciences, FITC-labeled ODN2006 was from InvivoGen, Alexa Fluor 488/cholera toxin subunit B (CTXB) and Alexa Fluor 568/transferrin were from Molecular Probes. MALP-2 was obtained from Biosynthesis (Nagoya, Japan). In addition, the following antibodies were used in this study: anti-dsRNA mAb (K1) (BioLink), anti-β actin mAb (Sigma), anti-clathrin heavy chain mAb (TD.1) (Santa Cruz Biotechnology), anti-Rab5 mAb (Abcam), anti-LAMP1 (H4A3) (BioLegend), HRP-conjugated secondary Abs (BIOSOURCE), FITC-labeled goat anti-mouse IgG (American Qualex), and Alexa Fluorp®-conjugated secondary antibodies (Invitrogen). Anti-human Raftlin polyclonal antibody was prepared as described (29). Anti-human TLR3 mAb (clone TLR3.7) was generated in our laboratory (5). Texas Red-labeled poly(I:C) was prepared using the 5′ EndTag™ Nucleic Acid Labeling System (Vector Laboratories, Burlingame, CA) according to the manufacturer's instructions.

Mice—Raftlin$^{-/-}$ mice were provided by Dr. A. Yoshimura (Keio University). Mice were maintained under specific pathogen-free conditions in the animal facility of the Hokkaido University Graduate School of Medicine. Animal experiments were performed according to the guidelines established by the Hokkaido University Animal Care and Use Committee.

Plasmids—The cDNA fragment encoding the ORF of human TLR2 or TLR3 was amplified by RT-PCR from total RNA prepared from MoDCs, and was ligated into the cloning site of the expression vector pEF-BOS, a gift from Dr. S. Nagata (Kyoto University) (5). Complementary DNA for human Raftlin was generated by PCR from cDNA derived from Raji cells using specific primers (forward primer, 5′-CTCGAGGCCGCCACCATGGGTTG-3′; reverse primer, 5′-GGATCCTTGTTTTCTTCAACCGTACCAAGCTC-3′), and was ligated into the cloning site of the expression vector pEYFP-N1 (C-terminal yellow fluorescent protein (YFP) tag, Clontech).



FIGURE 1. **Raftlin participates in poly(I:C)-induced TLR3-mediated signaling.** HEK293 cells were transfected with the indicated siRNAs (20 pmol) together with the expression vector for human TLR3 (*A*, *B*, and *D*), human TLR2 (*C*), or empty vector and reporter plasmid. Forty-eight hours after transfection, cells were washed and stimulated with 10–30 μg/ml of poly(I:C) or 200 nM MALP-2. After 6 h, the luciferase reporter activities were measured and expressed as fold-induction relative to the activity of unstimulated vector-transfected cells. Representative data from a minimum of three separate experiments are shown (mean ± S.D.). In each experiment, knockdown (*KD*) efficiency was assessed 48 h after transfection by qPCR. Expression of each gene was normalized to GAPDH mRNA expression. As shown in the *right-hand panels* of *A*, expression of the indicated genes is efficiently silenced (knockdown efficiency: TICAM-1, 91.4%; LYRIC, 89.5%; 4F2, 77.4%; Raftlin, 71.8%). *, $p < 0.05$ (*t* test).

Isolation of Poly(I:C)-binding Proteins—Raji cells (1×10^{10}) were washed twice with Dulbecco's phosphate-buffered saline, frozen and thawed three times in Dulbecco's phosphate-buffered saline (5×10^7/ml), and centrifuged at 20,000 × *g* for 10 min. Cell pellets were lysed in lysis buffer (1% Nonidet P-40 in buffer A (20 mM Tris-HCl, pH 7.4, 140 mM NaCl, 25 mM iodoacetamide, 10 mM EDTA, 2 mM PMSF and protease inhibitor mixture)) for 20 min at room temperature. After centrifugation at 10,000 × *g* for 10 min, supernatants were filtrated with Minisalt GF (Zartorius stedim, Japan) and sequentially applied to Sepharose, poly(U)-Sepharose, and poly(I:C)-Sepharose equilibrated with binding buffer (0.2% Nonidet P-40 in buffer A). The poly(I:C)-binding molecules were eluted from poly(I:C)-Sepharose with elution buffer (1.4 M NaCl in washing buffer) after being washed with washing buffer (10 mM CHAPS in buffer A). The eluates were